Skip to main content
Top
Published in: Tumor Biology 3/2016

01-03-2016 | Original Article

RETRACTED ARTICLE: Tissue expression levels of miR-29b and miR-422a in children, adolescents, and young adults’ age groups and their association with prediction of poor prognosis in human osteosarcoma

Authors: Reza Bahador, Afshin Taheriazam, Alireza Mirghasemi, Ali Torkaman, Mohammadreza Shakeri, Emad Yahaghi, Peyman Karimi Goudarzi

Published in: Tumor Biology | Issue 3/2016

Login to get access

Abstract

Osteosarcoma is the most common type of bone cancer in children and adolescents. MicroRNAs (miRNAs) play important roles in the development, differentiation, and function of different cell types and in the pathogenesis of various human diseases. miRNAs are differentially expressed in normal and cancer cells. The investigation of miRNA expression between healthy subjects and patients with osteosarcoma is crucial for future clinical trials. In this study, the expression levels of miRNAs were detected by qRT-PCR. Correlation between expression levels of tow miRNAs and different clinicopathological characteristics were analyzed using the χ 2 test. Survival rate was detected using the log-rank test and Kaplan–Meier method. qRT-PCR was shown that expression levels of miR-29b and miR-422a were strongly decreased in osteosarcoma bone tissue compared with noncancerous bone tissues. Our result indicated that the low expression levels of miR-29b and miR-422a showed strong correlation with large tumor size (P = 0.20; 0.029), advanced TNM stage (P = 0.001; 0.012), distant metastasis (P = 0.008; 0.019), and grade of tumor (P = 0.009; 0.016). Kaplan–Meier survival analysis showed that the low expressions of miR-29b/miR-422a were correlated with shorter time overall survival (log-rank test, P = 0.009; P = 0.013). Moreover, multivariate Cox proportional hazards model indicated that miR-29b and miR-422a (P = 0.024; P = 0.016) were independent prognostic markers of overall survival of patients. Our result indicated that downregulation of miR-29b and miR-422a may be linked to the prediction of poor prognosis, indicating that miR-29b and miR-422a may be a valuable prognostic marker for osteosarcoma patients.
Literature
1.
3.
go back to reference Leary SE, Wozniak AW, Billups CA, Wu J, McPherson V, Neel MD. Survival of pediatric patients after relapsed osteosarcoma: the St. Jude Children’s Research Hospital experience. Cancer. 2013;119(14):2645–53.CrossRefPubMedPubMedCentral Leary SE, Wozniak AW, Billups CA, Wu J, McPherson V, Neel MD. Survival of pediatric patients after relapsed osteosarcoma: the St. Jude Children’s Research Hospital experience. Cancer. 2013;119(14):2645–53.CrossRefPubMedPubMedCentral
4.
go back to reference Kager L, Zoubek A, Kastner U, Kempf-Bielack B, Potratz J, Kotz R. Skip metastases in osteosarcoma: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol. 2006;24(10):1535–41.CrossRefPubMed Kager L, Zoubek A, Kastner U, Kempf-Bielack B, Potratz J, Kotz R. Skip metastases in osteosarcoma: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol. 2006;24(10):1535–41.CrossRefPubMed
5.
go back to reference Henry JC, Park JK, Jiang J, Kim JH, Nagorney DM, Roberts LR, et al. miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines. Biochem Biophys Res Commun. 2010;403:120–5.CrossRefPubMedPubMedCentral Henry JC, Park JK, Jiang J, Kim JH, Nagorney DM, Roberts LR, et al. miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines. Biochem Biophys Res Commun. 2010;403:120–5.CrossRefPubMedPubMedCentral
6.
go back to reference Baumhoer D, Zillmer S, Unger K, Rosemann M, Atkinson MJ, Irmler M. MicroRNA profiling with correlation to gene expression revealed the oncogenic miR-17-92 cluster to be up-regulated in osteosarcoma. Cancer Genet. 2012;205(5):212–9.CrossRefPubMed Baumhoer D, Zillmer S, Unger K, Rosemann M, Atkinson MJ, Irmler M. MicroRNA profiling with correlation to gene expression revealed the oncogenic miR-17-92 cluster to be up-regulated in osteosarcoma. Cancer Genet. 2012;205(5):212–9.CrossRefPubMed
7.
go back to reference Jin J, Cai L, Liu ZM, Zhou XS. miRNA-218 Inhibits osteosarcoma cell migration and invasion by down-regulating of TIAM1, MMP2 and MMP9. Asian Pac J Cancer Prev. 2013;14(6):3681–4.CrossRefPubMed Jin J, Cai L, Liu ZM, Zhou XS. miRNA-218 Inhibits osteosarcoma cell migration and invasion by down-regulating of TIAM1, MMP2 and MMP9. Asian Pac J Cancer Prev. 2013;14(6):3681–4.CrossRefPubMed
8.
go back to reference Jones KB, Salah Z, Del Mare S, Galasso M, Gaudio E, Nuovo GJ. miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res. 2012;72(7):1865–77.CrossRefPubMedPubMedCentral Jones KB, Salah Z, Del Mare S, Galasso M, Gaudio E, Nuovo GJ. miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res. 2012;72(7):1865–77.CrossRefPubMedPubMedCentral
9.
go back to reference Sun Y, Fang R, Li C, Li L, Li F, Ye X. Hsa-mir-182 suppresses lung tumorigenesis through down regulation of RGS17 expression in vitro. Biochem Biophys Res Commun. 2010;396(2):501–7.CrossRefPubMed Sun Y, Fang R, Li C, Li L, Li F, Ye X. Hsa-mir-182 suppresses lung tumorigenesis through down regulation of RGS17 expression in vitro. Biochem Biophys Res Commun. 2010;396(2):501–7.CrossRefPubMed
10.
go back to reference Kwiecinski M, Elfimova N, Noetel A, Tox U, Steffen HM, Hacker U, et al. Expression of platelet-derived growth factor-c and insulin-like growth factor i in hepatic stellate cells is inhibited by miR-29. Lab Invest. 2012;92:978–87.CrossRefPubMed Kwiecinski M, Elfimova N, Noetel A, Tox U, Steffen HM, Hacker U, et al. Expression of platelet-derived growth factor-c and insulin-like growth factor i in hepatic stellate cells is inhibited by miR-29. Lab Invest. 2012;92:978–87.CrossRefPubMed
11.
go back to reference Dai N, Zhong ZY, Cun YP, Qing Y, Chen C, Jiang P, et al. Alteration of the microRNA expression profile in human osteosarcoma cells transfected with APE1 siRNA. Neoplasma. 2013;60:384–94.CrossRefPubMed Dai N, Zhong ZY, Cun YP, Qing Y, Chen C, Jiang P, et al. Alteration of the microRNA expression profile in human osteosarcoma cells transfected with APE1 siRNA. Neoplasma. 2013;60:384–94.CrossRefPubMed
12.
go back to reference Hong Q, Fang J, Pang Y. Prognostic value of the microRNA-29 family in patients with primary osteosarcomas. Med Oncol. 2014;31:37.CrossRefPubMed Hong Q, Fang J, Pang Y. Prognostic value of the microRNA-29 family in patients with primary osteosarcomas. Med Oncol. 2014;31:37.CrossRefPubMed
13.
go back to reference Gougelet A, Pissaloux D, Besse A, Perez J, Duc A. Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. Int J Cancer. 2011;129:680–90.CrossRefPubMed Gougelet A, Pissaloux D, Besse A, Perez J, Duc A. Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. Int J Cancer. 2011;129:680–90.CrossRefPubMed
14.
go back to reference Wu XJ, Li Y, Liu D, Zhao LD, Bai B, Xue MH. MiR-27a as an oncogenic microRNA of hepatitis B virus-related hepatocellular carcinoma. Asian Pac J Cancer Prev. 2013;14:885–9.CrossRefPubMed Wu XJ, Li Y, Liu D, Zhao LD, Bai B, Xue MH. MiR-27a as an oncogenic microRNA of hepatitis B virus-related hepatocellular carcinoma. Asian Pac J Cancer Prev. 2013;14:885–9.CrossRefPubMed
15.
go back to reference Zhao G, Cai C, Yang T. MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PLoS One. 2013;8(1):e53906.CrossRefPubMedPubMedCentral Zhao G, Cai C, Yang T. MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PLoS One. 2013;8(1):e53906.CrossRefPubMedPubMedCentral
16.
go back to reference Huang J, Gao K, Lin J. MicroRNA-100 inhibits osteosarcoma cell proliferation by targeting Cyr61. Tumor Biol. 2014;35(2):1095–100.CrossRef Huang J, Gao K, Lin J. MicroRNA-100 inhibits osteosarcoma cell proliferation by targeting Cyr61. Tumor Biol. 2014;35(2):1095–100.CrossRef
17.
go back to reference Sandhu R, Rivenbark AG, Mackler RM, Livasy CA, Coleman WB. Dysregulation of microRNA expression drives aberrant DNA hypermethylation in basal-like breast cancer. Int J Oncol. 2014;44:563–72.PubMed Sandhu R, Rivenbark AG, Mackler RM, Livasy CA, Coleman WB. Dysregulation of microRNA expression drives aberrant DNA hypermethylation in basal-like breast cancer. Int J Oncol. 2014;44:563–72.PubMed
18.
go back to reference Cheng J, Guo S, Chen S. An extensive network of TET2-targeting microRNAs regulates malignant hematopoiesis. Cell Rep. 2013;5(2):471–81.CrossRefPubMed Cheng J, Guo S, Chen S. An extensive network of TET2-targeting microRNAs regulates malignant hematopoiesis. Cell Rep. 2013;5(2):471–81.CrossRefPubMed
19.
go back to reference Faltejskova P, Svoboda M, Srutova K, Mlcochova J, Besse A. Identification and functional screening of microRNAs highly deregulated in colorectal cancer. J Cell Mol Med. 2012;16:2655–66.CrossRefPubMedPubMedCentral Faltejskova P, Svoboda M, Srutova K, Mlcochova J, Besse A. Identification and functional screening of microRNAs highly deregulated in colorectal cancer. J Cell Mol Med. 2012;16:2655–66.CrossRefPubMedPubMedCentral
20.
go back to reference Yan B, Guo Q, Fa-jun F, Wang Z, Yin Z, Wei Y-b, et al. The role of miR-29b in cancer: regulation, function, and signaling. Onco Targets Ther. 2015;8:539–48.PubMedPubMedCentral Yan B, Guo Q, Fa-jun F, Wang Z, Yin Z, Wei Y-b, et al. The role of miR-29b in cancer: regulation, function, and signaling. Onco Targets Ther. 2015;8:539–48.PubMedPubMedCentral
Metadata
Title
RETRACTED ARTICLE: Tissue expression levels of miR-29b and miR-422a in children, adolescents, and young adults’ age groups and their association with prediction of poor prognosis in human osteosarcoma
Authors
Reza Bahador
Afshin Taheriazam
Alireza Mirghasemi
Ali Torkaman
Mohammadreza Shakeri
Emad Yahaghi
Peyman Karimi Goudarzi
Publication date
01-03-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 3/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4140-5

Other articles of this Issue 3/2016

Tumor Biology 3/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine